License Agreement Between Mycenax and RIN
Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, has signed a License Agreement with Japan-based RIN Institute Inc.
The agreement grants Mycenax rights to apply RIN's proprietary Val-Leu-Lys (VLK) linker technology in CDMO services worldwide.
RIN's VLK linker has demonstrated superior anti-tumor efficacy and high serum stability, enabling the development of advanced ADCs.
- The VLK linker facilitates cytotoxicity through two mechanisms:
- action within the tumor microenvironment
- enhanced ADC internalization
RIN's VLK linker technology will strengthen Mycenax's capability to deliver differentiated ADC solutions for global pharmaceutical partners.
Author's summary: Mycenax and RIN sign license agreement.
More News
- JUST IN: Kelly Olynyk has been waived by the San Antonio Spurs
- Jay Kelly cast guide: All on which characters George Clooney, Adam Sandler and Laura Dern play in the film
- Kelly Massol : « J’ai réalisé 40% de mon ambition »
- Spurs' Kelly Olynyk: Ongoing Decline in Playing Time and Role
- How to watch Islanders vs. Lightning: TV channel and streaming options for December 6
- NBA: Spurs at Timberwolves
- When does 2026 F1 season start?
- Lightning vs. Islanders Prediction, Odds, Picks - Dec. 6
- Kelly Osbourne — Instagram Snapshot
- Guadeloupean artist Kelly Sinnapah Mary wins French art prize at Art Basel Miami Beach